CD34+ Stem Cell Therapy for Infarct Perfusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are insufficient in addressing long-term adverse consequences of vascular insufficiency after myocardial infarction, particularly in improving infarct-area perfusion and preventing ventricular remodeling.
Innovation Solution
Administration of a sterile pharmaceutical composition containing a nonexpanded, isolated chemotactic hematopoietic stem cell product enriched with CD34+ cells expressing CXCR-4, which are infused via a catheter to improve perfusion in the infarct area, promoting cardiomyocyte growth and neoangiogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for myocardial infarction treatment, then immediate life-saving intervention is achieved, but long-term adverse consequences of vascular insufficiency and ventricular remodeling persist
Solution Approach 1:
The patent administers hematopoietic stem cells at a specific time window (5-14 days post-infarction) after the acute phase has passed and before permanent scar formation completes. This preliminary action during the critical remodeling phase promotes neoangiogenesis and prevents adverse ventricular remodeling before it becomes irreversible, thereby extending therapeutic benefit from immediate to long-term.
Solution Approach 2:
The hematopoietic stem cells act as intermediary agents that mediate between the infarcted tissue and the healing process. These cells differentiate into endothelial cells and promote neoangiogenesis, serving as a bridge to restore blood flow and prevent vascular insufficiency. The cells also modulate inflammation and promote tissue repair, thereby extending therapeutic effects long-term.
2Quantity of substance
If revascularization procedures are performed, then blood flow is restored to the infarct area, but perfusion in the infarct area and hibernating myocardium remains insufficient
Solution Approach 1:
The patent changes the biological parameter of the tissue by introducing hematopoietic stem cells that differentiate into endothelial cells. This increases the number of functional blood vessels (neoangiogenesis) in the infarct area and hibernating myocardium, thereby improving perfusion adequacy beyond what mechanical revascularization alone can achieve.
Solution Approach 2:
While revascularization procedures address the macrovascular dimension (large arteries), the patent adds a microvascular dimension by promoting neoangiogenesis at the capillary level. This multi-dimensional approach ensures adequate perfusion throughout the entire tissue, including areas that were previously underperfusioned despite successful revascularization.
3Ease of operation
If no additional therapy is given after revascularization, then treatment simplicity is maintained, but infarct area injury progresses and ventricular remodeling occurs
Solution Approach 1:
The patent employs autologous hematopoietic stem cells that the patient's own body provides. These cells are mobilized, collected, and reinfused, leveraging the body's innate regenerative capacity. This self-service approach promotes healing and prevents infarct area injury progression without requiring complex external interventions, maintaining relative treatment simplicity while improving outcomes.
Solution Approach 2:
The hematopoietic stem cells serve as intermediary agents that mediate the healing process between the infarcted tissue and the body's natural repair mechanisms. These cells modulate inflammation, promote neoangiogenesis, and facilitate tissue repair, thereby preventing infarct area injury progression and adverse ventricular remodeling with a relatively simple cellular therapy approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly improves resting perfusion rates and reduces infarct area injury, enhancing cardiac function by increasing perfusion in ischemic peri-infarct zones and hibernating myocardium, thereby limiting adverse ventricular remodeling.
Implementation Method 1
enriched population of isolated autologous CD34+ cells containing a subpopulation of potent cells expressing CXCR-4 and having CXCR-4 mediated chemotactic activity
Data Source
AI summary
The described invention provides pharmaceutical compositions for treating an infarct area injury and methods of treating or repairing the infarct area injury in a revascularized subject in the aftermath of an acute myocardial infarction resulting from a natural disease process by administering to the subject parenterally through a catheter a sterile pharmaceutical composition containing a therapeutically effective amount of a nonexpanded sterile isolated chemotactic hematopoietic stem cell product as a first therapeutic agent and optionally a therapeutically effective amount of at least one compatible second therapeutic agent. The infarct area-improving amount of the sterile isolated chemotactic hematopoietic stem cell product comprises an enriched population of isolated autologous CD34+ cells containing a subpopulation of potent cells expressing CXCR-4 and having CXCR-4-mediated chemotactic activity such that the enriched population of isolated autologous CD34+ hematopoietic stem cells provides at least 0.5×106 potent CD34+ cells expressing CXCR-4 and having CXCR-4 mediated chemotactic activity.